Education
About Us
Working with TipRanks
Follow Us
Sirnaomics Ltd. (HK:2257)
:2257
2257 Stock Chart & Stats
HK$8.00
-HK$0.09(-2.79%)
At close: 4:00 PM EST
HK$8.00
-HK$0.09(-2.79%)
Day’s Range― - ―
52-Week RangeHK$2.83 - HK$22.78
Previous CloseN/A
Volume36.40K
Average Volume (3M)442.62K
Market Cap
HK$782.72M
Enterprise ValueHK$99.19M
Total Cash (Recent Filing)HK$6.87M
Total Debt (Recent Filing)HK$7.21M
Price to Earnings (P/E)―
Beta1.62
Next Earnings
Mar 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.31
Shares Outstanding107,221,535
10 Day Avg. Volume408,789
30 Day Avg. Volume442,620
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-20.53
Price to Sales (P/S)19.40
P/FCF Ratio-1.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary RNAi Platform & PartnershipsA proprietary siRNA design and optimization platform plus academic and pharma collaborations provide durable R&D and commercialization advantages. These assets support sustained pipeline development, licensing opportunities, and reduced time-to-market vs. newcomers, bolstering long-term competitivenes.
Strong Product-level Gross MarginsA 67.4% gross margin indicates the underlying science and manufacturing economics can be attractive once scale is reached. High product-level margins give the company room to invest in clinical development and cover fixed R&D overheads, improving long-term viability if revenue scales.
Improving Free Cash Flow TrendPositive movement in free cash flow year-over-year signals improving cash conversion and operational discipline. If sustained, this reduces reliance on external financing, lowers dilution risk, and supports funding of clinical programs and partnerships over the coming 2-6 months and beyond.
Bears Say
Negative Stockholders' EquityNegative equity is a structural solvency concern that limits financial flexibility and access to capital. Over months this raises default and covenant risk, can deter partners or lenders, and may force dilutive financing or asset sales to sustain operations if cash burn persists.
Deeply Negative Net And Operating MarginsSeverely negative net and operating margins reflect persistent losses from high development and operating costs. Structurally, these margins impede retained earnings growth, require recurring external funding, and increase execution risk for advancing expensive clinical programs over the medium term.
Operating Expense Burden Vs. Gross ProfitHigh operating expenses that outstrip healthy gross margins indicate structural inefficiencies or heavy R&D/SG&A commitments. Without sustained revenue growth or expense reduction, cash burn will continue, straining liquidity and limiting ability to fund late-stage development and commercialization efforts.
Sirnaomics Ltd. News
2257 FAQ
What was Sirnaomics Ltd.’s price range in the past 12 months?
Sirnaomics Ltd. lowest stock price was HK$2.83 and its highest was HK$22.78 in the past 12 months.
What is Sirnaomics Ltd.’s market cap?
Sirnaomics Ltd.’s market cap is HK$782.72M.
When is Sirnaomics Ltd.’s upcoming earnings report date?
Sirnaomics Ltd.’s upcoming earnings report date is Mar 26, 2026 which is in 31 days.
How were Sirnaomics Ltd.’s earnings last quarter?
Sirnaomics Ltd. released its earnings results on Aug 28, 2025. The company reported -HK$0.311 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.311.
Is Sirnaomics Ltd. overvalued?
According to Wall Street analysts Sirnaomics Ltd.’s price is currently Overvalued.
Does Sirnaomics Ltd. pay dividends?
Sirnaomics Ltd. does not currently pay dividends.
What is Sirnaomics Ltd.’s EPS estimate?
Sirnaomics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sirnaomics Ltd. have?
Sirnaomics Ltd. has 107,221,535 shares outstanding.
What happened to Sirnaomics Ltd.’s price movement after its last earnings report?
Sirnaomics Ltd. reported an EPS of -HK$0.311 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -8.205%.
Which hedge fund is a major shareholder of Sirnaomics Ltd.?
Currently, no hedge funds are holding shares in HK:2257
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sirnaomics Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
207.69%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-38.03%
Trailing 12-Months
Company Description
Sirnaomics Ltd.
Sirnaomics Ltd., an RNA therapeutics biopharmaceutical company, focuses on the discovery and development of product candidates for indications with medical needs in the United Sates and the People's Republic of China. Its lead product candidates include STP705 for the treatment cutaneous squamous cell carcinoma in situ; basal cell carcinoma; cholangiocarcinoma, hepatocellular carcinoma, liver metastases, etc.; keloid scarless healing, hypertrophic scarring, and fat sculpting. The company's lead product candidates also comprise STP707 to treat cholangiocarcinoma, hepatocellular carcinoma, liver metastases, etc.; metastatic cutaneous squamous cell carcinoma; non-small cell lung cancer; liver fibrosis; and lung fibrosis. It also develops STP355 for the treatment of pan cancer; STP369 to treat head and neck/bladder cancer; STP779 for the treatment of liver/lung/pancreatic cancer; STP902 to treat breast cancer; STP702 for the treatment of influenza; STP908 to treat COVID-19; RIM730 COVID-19 vaccine; STP909 for the treatment of HPV/cervical cancer; and STP122G for thrombotic disorders. In addition, the company is developing STP125G to treat hypertriglyceridemia; STP144G for the treatment of complement-mediated diseases; STP133G for cardiometabolic; and STP155G for the treatment hepatitis B virus. Sirnaomics Ltd. was founded in 2007 and is headquartered in Gaithersburg, Maryland.
Technical Analysis
TOT BIOPHARM International Co. Ltd.
―
Clover Biopharmaceuticals Ltd.
―
CStone Pharmaceuticals
―
SinoMab Bioscience Ltd.
―
Transcenta Holding Limited
―